Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in Rats: Possible role of CYP3A4 and P-glycoprotein inhibition by myricetin

Archives of Pharmacal Research

Volumn 34, Issue 2, 2011, Pages 309-315

  Choi, Sang Joon ^a   Shin, Sang Chul ^b   Choi, Jun Shik ^a  

^a Chosun University   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

Bioavailability; CYP3A4; Doxorubicin; Myricetin; P gp; Pharmacokinetics; Rats

Indexed keywords

CYTOCHROME P450 3A4; DOXORUBICIN; GLYCOPROTEIN P; MYRICETIN; RHODAMINE 123;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; GENE OVEREXPRESSION; MALE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; DOXORUBICIN; DRUG INTERACTIONS; FLAVONOIDS; INJECTIONS, INTRAVENOUS; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79953299941     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-011-0217-x     Document Type: Article

References (32)

1. Alarcón de la Lastra, C., Martín, M. J., and Motilva, V., Antiulcer and gastroprotective effects of quercetin: a gross and histologic study. Pharmacology, 48, 56-62 (1994).
2. Andersen, A., Warren, D. J., and Slordal, L., A sensitive and simple high-performance liquid chromatographic method for the determination of doxorubicin and its metabolites in plasma. Ther. Drug Monit., 15, 455-461 (1993).
3. Bogaards, J. J., Bertrand, M., Jackson, P., Oudshoorn, M. J., Weaver, R. J., van Bladeren, P. J., and Walther, B., Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica, 30, 1131-1152 (2000).
4. Cao, X., Gibbs, S. T., Fang, L., Miller, H. A., Landowski, C. P., Shin, H. C., Lennernas, H., Zhong, Y., Amidon, G. L., Yu, L. X., and Sun, D., Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res., 23, 1675-1686 (2006).
5. Cordon-Cardo, C., O'Brien, J. P., Casals, D., Bertino, J. R., and Melamed, M. R., Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem., 38, 1277-1287 (1990).
6. Crespi, C. L., Miller, V. P., and Penman, B. W., Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem., 248, 188-190 (1997).
7. Cummins, C. L., Jacobsen, W., and Benet, L. Z., Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther., 300, 1036-1045 (2002).
8. Dixon, R. A. and Steele, C. L., Flavonoids and isoflavonoids - a gold mine for metabolic engineering. Trends Plant Sci., 4, 394-400 (1999).
9. Fakhoury, M., Litalien, C., Medard, Y., Cave, H., Ezzahir, N., Peuchmaur, M., and Jacqz-Aigrain, E., Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab. Dispos., 33, 1603-1607 (2005).
10. Fojo, A. T., Shen, D. W., Mickley, L. A., Pastan, I., and Gottesman, M. M., Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J. Clin. Oncol., 5, 1922-1927 (1987).
11. Gibaldi, M. and Perrier, D., Pharmacokinetics (2nd edn), Marcel-Dekker, New York, (1982).
12. Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P., Wolff, T., and Waxman, D. J., Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem., 261, 5051-5060 (1986).
13. Gustafson, D. L., Merz, A. L., and Long, M. E., Pharmacokinetics of combined doxorubicin and paclitaxel in mice. Cancer Lett., 220, 161-169 (2005).
14. Häkkinen, S. H., Kärenlampi, S. O., Heinonen, I. M., Mykkänen, H. M., and Törrönen, A. R., Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J. Agric. Food Chem., 47, 2274-2279 (1999).
15. Ito, K., Kusuhara, H., and Sugiyama, Y., Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorptiontheoretical approach. Pharm. Res., 16, 225-231 (1999).
16. Kelly, P. A., Wang, H., Napoli, K. L., Kahan, B. D., and Strobel, H. W., Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur. J. Drug Metab. Pharmacokinet., 24, 321-328 (1999).
17. Kitagawa, S., Nabekura, T., Takahashi, T., Nakamura, Y., Sakamoto, H., Tano, H., Hirai, M., and Tsukahara, G., Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KBC2 cells. Biol. Pharm. Bull., 28, 2274-2278 (2005).
18. Lee, H. J. and Lee, M. G., Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. Res. Commun. Mol. Pathol. Pharmacol., 105, 87-96 (1999).
19. Lewis, D. F. V., Cytochrome P450. Substrate specificity and metabolism. In Cytochromes P450. Structure, Function, and Mechanism. Taylor & Francis, Bristol, pp. 122-123, (1996).
20. Merkel, D. E., Fuqua, S. A. W., Tandom, A. K., Hill, S. M., Buzdar, A. U., and McGuire, W. L., Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression of gene amplification. J. Clin. Oncol., 7, 1129-1136 (1989).
21. Nijveldt, R. J., van Nood, E., van Hoorn, D. E., Boelens, P. G., van Norren, K., and van Leeuwen, P. A., Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr., 74, 418-425 (2001).
22. Ohnishi, E. and Bannai, H., Quercetin potentiates TNF-induced antiviral activity. Antiviral Res., 22, 327-331 (1993).
23. Pichard, L., Gillet, G., Fabre, I., Dalet-Beluche, I., Bonfils, C., Thenot, J. P., and Maurel, P., Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab. Dispos., 18, 711-719 (1990).
24. Shin, S. C., Li, C., and Choi, J. S., Effects of baicalein, an antioxidant, on the bioavailability of doxorubicin in rats: possible role of P-glycoprotein inhibition by baicalein. Pharmazie, 64, 579-583 (2009).
25. Smylie, M. G., Wong, R., Mihalcioiu, C., Lee, C., and Pouliot, J. F., A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma. Invest. New Drugs, 25, 155-159 (2007).
26. Speth, P. A. J., van Hoesel, Q. G., and Haanen, C., Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet., 15, 15-31 (1988).
27. Takahama, U., Inhibition of lipoxygenase-dependent lipid peroxidation by quercetin: Mechanism of antioxidative function. Phytochemistry, 24, 1443-1446 (1985).
28. Václavíková, R., Horský, S., Simek, P., and Gut, I., Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn. Schmiedebergs Arch. Pharmacol., 368, 200-209 (2003).
29. von Moltke, L. L., Weemhoff, J. L., Bedir, E., Khan, I. A., Harmatz, J. S., Goldman, P., and Greenblatt, D. J., Inhibition of human cytochromes P450 by components of Ginkgo biloba. J. Pharm. Pharmacol., 56, 1039-1044 (2004).
30. Wacher, V. J., Silverman, J. A., Zhang, Y., and Benet, L. Z., Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci., 87, 1322-1330 (1998).
31. Wang, E., Lew, K., Barecki, M., Casciano, C. N., Clement, R. P., and Johnson, W. W., Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem. Res. Toxicol., 14, 1596-1603 (2001).
32. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G., and Siegel, G., Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol., 10, 1439-1443 (2000).